Pharma Industry News

Pfizer’s abrocitinib hits endpoints in late-stage atopic dermatitis study

The data will support filings with regulatory bodies, starting with the FDA later this year.Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]